Abstract
Polymerized bovine hemoglobin is currently under investigation as an alternative to blood-banked human red blood cells. Because of the dark red hemolyzed appearance of hemoglobin-based oxygen carrier (HBOC)-201, we sought to describe the effects of HBOC-201 on coagulation analyzers that perform prothrombin times, activated partial thromboplastin times, fibrinogen, and antithrombin. Pooled normal plasma was combined with HBOC-201 to achieve plasma hemoglobin levels of 1.4, 2.6, 3.8, 4.8, and 6.2 g/dL. Results for each test using HBOC-201-prepared plasma were compared with results using saline-matched controls. Two consecutive absolute result differences of >10% between saline controls and HBOC-201 samples were used for determining interference in test accuracy by the concentration of HBOC-201. Mechanical detection methods (fibrometer, STA, CS-190) and the MDA-180 method were less affected by increasing levels of HBOC-201 than optical detection devices for all test parameters.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 431-436 |
| Number of pages | 6 |
| Journal | American Journal of Therapeutics |
| Volume | 9 |
| Issue number | 5 |
| State | Published - Sep 2002 |
Fingerprint
ASJC Scopus subject areas
- Pharmacology
Cite this
Effects of hemoglobin glutamer-250 (bovine) (HBOC-201, Hemopure) on coagulation testing. / Jahr, Jonathan S.; Lurie, Fedor; Gosselin, Robert; Lin, Jonathan S.; Wong, Luchin; Owings, John T; Larkin, Edward.
In: American Journal of Therapeutics, Vol. 9, No. 5, 09.2002, p. 431-436.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Effects of hemoglobin glutamer-250 (bovine) (HBOC-201, Hemopure) on coagulation testing.
AU - Jahr, Jonathan S.
AU - Lurie, Fedor
AU - Gosselin, Robert
AU - Lin, Jonathan S.
AU - Wong, Luchin
AU - Owings, John T
AU - Larkin, Edward
PY - 2002/9
Y1 - 2002/9
N2 - Polymerized bovine hemoglobin is currently under investigation as an alternative to blood-banked human red blood cells. Because of the dark red hemolyzed appearance of hemoglobin-based oxygen carrier (HBOC)-201, we sought to describe the effects of HBOC-201 on coagulation analyzers that perform prothrombin times, activated partial thromboplastin times, fibrinogen, and antithrombin. Pooled normal plasma was combined with HBOC-201 to achieve plasma hemoglobin levels of 1.4, 2.6, 3.8, 4.8, and 6.2 g/dL. Results for each test using HBOC-201-prepared plasma were compared with results using saline-matched controls. Two consecutive absolute result differences of >10% between saline controls and HBOC-201 samples were used for determining interference in test accuracy by the concentration of HBOC-201. Mechanical detection methods (fibrometer, STA, CS-190) and the MDA-180 method were less affected by increasing levels of HBOC-201 than optical detection devices for all test parameters.
AB - Polymerized bovine hemoglobin is currently under investigation as an alternative to blood-banked human red blood cells. Because of the dark red hemolyzed appearance of hemoglobin-based oxygen carrier (HBOC)-201, we sought to describe the effects of HBOC-201 on coagulation analyzers that perform prothrombin times, activated partial thromboplastin times, fibrinogen, and antithrombin. Pooled normal plasma was combined with HBOC-201 to achieve plasma hemoglobin levels of 1.4, 2.6, 3.8, 4.8, and 6.2 g/dL. Results for each test using HBOC-201-prepared plasma were compared with results using saline-matched controls. Two consecutive absolute result differences of >10% between saline controls and HBOC-201 samples were used for determining interference in test accuracy by the concentration of HBOC-201. Mechanical detection methods (fibrometer, STA, CS-190) and the MDA-180 method were less affected by increasing levels of HBOC-201 than optical detection devices for all test parameters.
UR - http://www.scopus.com/inward/record.url?scp=0036728110&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036728110&partnerID=8YFLogxK
M3 - Article
C2 - 12237736
AN - SCOPUS:0036728110
VL - 9
SP - 431
EP - 436
JO - American Journal of Therapeutics
JF - American Journal of Therapeutics
SN - 1075-2765
IS - 5
ER -